CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
Open Access
- 27 March 2025
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 15 (5) , 1079-1092
Abstract
Introduction A 27-week analysis of this phase 3 study demonstrated the interchangeability of the adalimumab biosimilar CT-P17 and reference adalimumab. The current 52-week analysis reports secondary data from the open-label extension period (OLE) of the study. Methods In this randomized, double-blind, active-controlled phase 3 study, adults with moderate-to-severe chronic plaque psoriasis received (via prefilled syringe) 80 mg subcutaneous reference adalimumab on day 1, then 40 mg 1 week later, and every other week (EOW) until week 11. At week 13, patients were randomized (1:1) to continue reference adalimumab (“continuous” group) or undergo repeated switching between CT-P17 and reference adalimumab (“switching” group) until week 25. Thereafter, patients entered an OLE and received 40 mg CT-P17 EOW from week 27 to 49, with an end-of-study visit at week 52. Here we present findings from the OLE. Pharmacokinetics (PK), efficacy (including mean percent improvement from baseline in Psoriasis Area Severity Index [PASI] score), safety, and immunogenicity were evaluated. Post hoc subgroup analyses were also conducted. Results Of 327 patients who initiated the OLE, 152 and 160 patients from the switching group and continuous group, respectively, completed the study. Mean serum concentrations were similar between groups throughout the OLE. Efficacy improvements observed up to week 27 were maintained during the OLE and were comparable between groups. At week 52, overall mean (standard deviation [SD]) improvement from baseline in PASI score was 90.34% (16.59). Safety profiles were similar between groups, and immunogenicity did not increase during the OLE. The mean (SD) percent improvement from baseline in PASI score was slightly lower in patients who were antidrug antibody (ADA)-positive versus those who were ADA-negative (89.57 [17.27] versus 97.29 [4.08]) at week 52. Conclusions PK, efficacy, safety, and immunogenicity findings remained consistent throughout the OLE, regardless of prior treatment, and were generally comparable across timepoints. Trial registration ClinicalTrials.gov: NCT05495568.Keywords
Funding Information
- Celltrion
This publication has 12 references indexed in Scilit:
- Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability StudyAdvances in Therapy, 2025
- Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidenceAutoimmunity Reviews, 2024
- Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisRheumatology, 2021
- Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjectsClinical and Translational Science, 2021
- Immunogenicity of biologic agents in rheumatologyNature Reviews Rheumatology, 2020
- A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteersJournal of Clinical Pharmacy and Therapeutics, 2017
- Extent and Consequences of Antibody Formation Against Adalimumab in Patients With PsoriasisJAMA Dermatology, 2014
- Adalimumab therapy for psoriasis in real‐world practice: efficacy, safety and results in biologic‐naïve vs. non‐naïve patientsJournal of the European Academy of Dermatology and Venereology, 2012
- Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEALJournal of the American Academy of Dermatology, 2012
- Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximabArthritis & Rheumatism, 2006